Search

Your search keyword '"MITSIAS, P"' showing total 1,185 results
Start Over "MITSIAS, P"

Refine your results

more »

more »

more »

more »

more »

more »

more »
1,185 results on '"MITSIAS, P"'

1. Editorial: Understanding PFO-associated stroke

Author

Theodoros Karapanayiotides, Vasileios-Arsenios Lioutas, Marta Rubiera, Gilles Montalescot, and Panayiotis Mitsias

Subjects
stroke, cryptogenic stroke, PFO (patent foramen ovale), right to left cardiac shunt, paradoxical embolism, Neurology. Diseases of the nervous system, RC346-429
Published
2023
Full Text
View/download PDF

2. Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce

Author

Julijana Asllani, Dimitrios Mitsias, George Konstantinou, Eris Mesonjesi, Fatmira Xhixha, Esmeralda Shehu, George Christoff, Katia Noleva, Michael Makris, Xenofon Aggelidis, Mirjana Turkalj, Erceg Damir, Ioana Agache, Vesna Tomic‐Spiric, Rajica Stosovic, Zeynep Misirligil, Mitja Kosnik, Todor A. Popov, Moises Calderon, Nikolaos G. Papadopoulos, and ADER study group

Subjects
adverse events, allergen immunotherapy, real‐life settings, risk factors, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Although it has been shown that allergen immunotherapy (AIT) is well‐tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed. Methods The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved. Patient‐ and AIT‐related features were collected and analyzed. The characteristics of adverse events (AE) and risk factors were evaluated. Results A total of 851 patients, 11.3 ± 3.4 years old, with rhinitis only (47.6%); asthma and rhinitis (44.5%); asthma (7.9%), receiving 998 AIT courses were analyzed. Sublingual immunotherapy (SLIT) accounted for 51% of the courses. In 84.5% of patients only one AIT treatment was prescribed. Pollen was the most frequent sensitizer (57.1%), followed by mites (53.4%), molds (18.2%) and epithelia (16.7%). Local and systemic AEs were reported in 85 patients (9.9%). Most AEs (83.1%) were mild and occurred in

Published
2023
Full Text
View/download PDF

3. The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project

Author

Julijana Asllani, Dimitrios Mitsias, George Konstantinou, Alfred Priftanji, Mehmet Hoxha, Gerta Sinani, George Christoff, Dimitrov Zlatko, Michael Makris, Xenofon Aggelidis, Asja Stipic, Sanja Popovic‐Grle, Diana Deleanu, Vesna Tomic‐Spiric, Aleksandra Plavsic, Dilsad Mungan, Mitja Kosnik, Todor A. Popov, Nikolaos G. Papadopoulos, Moises Calderon, and ADER study group

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2023
Full Text
View/download PDF

5. Effect of nasal irrigation on allergic rhinitis control in children; complementarity between CARAT and MASK outcomes

Author

Dimitrios I. Mitsias, Maria V. Dimou, John Lakoumentas, Konstantinos Alevizopoulos, Bernardo Sousa-Pinto, Joao A. Fonseca, Jean Bousquet, and Nikolaos G. Papadopoulos

Subjects
Allergic rhinitis, Nasal irrigations, Sea-water solution, CARAT questionnaire, MASK/Allergy Diary app, Children and adolescents, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Nasal irrigations (NI) are increasingly used as an over-the-counter adjunctive treatment for allergic rhinitis (AR), but clinical studies on their effectiveness are limited. Methods An open-label, controlled, non-randomized, real-life study was conducted to evaluate the effectiveness of NI with a new hypertonic solution as add-on treatment for AR. Children and adolescents with AR were prescribed symptomatic treatment. The active group also received an additional sea-water NI solution supplemented with algae extracts. The primary endpoint was symptom control, assessed by the control of allergic rhinitis and asthma test (CARAT) questionnaires. Moreover, the MASK/Allergy Diary was used to track symptoms and daily medication use that were combined in a novel total symptom/medication score (TSMS). Results We assessed 76 patients. Overall, there was a significant improvement of CARAT results (median Z-score change of 1.1 in the active/NI group vs. 0.4 in the control group; p = 0.035). Among patients > 12 years old (n = 51), there was a significant improvement in CARAT10 results among participants receiving NI (21.0 to 25.5; p

Published
2020
Full Text
View/download PDF

6. The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?

Author

Athina-Maria Aloizou, Georgia Pateraki, Vasileios Siokas, Alexios-Fotios A. Mentis, Ioannis Liampas, George Lazopoulos, Leda Kovatsi, Panayiotis D. Mitsias, Dimitrios P. Bogdanos, Konstantinos Paterakis, and Efthimios Dardiotis

Subjects
Glioma, Glioblastoma multiforme, miRNA-21, microRNA, oncomiR, Toxicology. Poisons, RA1190-1270
Abstract

Gliomas are the most common primary brain tumors in adults. They are generally very resistant to treatment and are therefore associated with negative outcomes. MicroRNAs (miRNAs) are small, non-coding RNA molecules that affect many cellular processes by regulating gene expression and, post-transcriptionally, the translation of mRNAs. MiRNA-21 has been consistently shown to be upregulated in glioma and research has shown that it is involved in a wide variety of biological pathways, promoting tumor cell survival and invasiveness. Furthermore, it has been implicated in resistance to treatment, both against chemotherapy and radiotherapy. In this review, we gathered the existent data on miRNA-21 and gliomas, in terms of its expression levels, association with grade and prognosis, the pathways it involves and its targets in glioma, and finally how it leads to treatment resistance. Furthermore, we discuss how this knowledge could be applied in clinical practice in the years to come. To our knowledge, this is the first review to assess in extent and depth the role of miRNA-21 in gliomas.

Published
2020
Full Text
View/download PDF

9. Optimization of risk stratification for anticoagulation-associated intracerebral hemorrhage: net risk estimation

Author

Lioutas, Vasileios-Arsenios, Goyal, Nitin, Katsanos, Aristeidis H., Krogias, Christos, Zand, Ramin, Sharma, Vijay K., Varelas, Panayiotis, Malhotra, Konark, Paciaroni, Maurizio, Karapanayiotides, Theodore, Sharaf, Aboubakar, Chang, Jason, Kargiotis, Odysseas, Pandhi, Abhi, Palaiodimou, Lina, Schroeder, Christoph, Tsantes, Argyrios, Boviatsis, Efstathios, Mehta, Chandan, Serdari, Aspasia, Vadikolias, Konstantinos, Mitsias, Panayiotis D., Selim, Magdy H., Alexandrov, Andrei V., and Tsivgoulis, Georgios

Published
2020
Full Text
View/download PDF

11. Acute reperfusion therapies for acute ischemic stroke patients with unknown time of symptom onset or in extended time windows: an individualized approach

Author

Georgios Magoufis, Apostolos Safouris, Guy Raphaeli, Odysseas Kargiotis, Klearchos Psychogios, Christos Krogias, Lina Palaiodimou, Stavros Spiliopoulos, Eftihia Polizogopoulou, Michael Mantatzis, Stephanos Finitsis, Theodore Karapanayiotides, John Ellul, Eleni Bakola, Elias Brountzos, Panayiotis Mitsias, Sotirios Giannopoulos, and Georgios Tsivgoulis

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Recent randomized controlled clinical trials (RCTs) have revolutionized acute ischemic stroke care by extending the use of intravenous thrombolysis and endovascular reperfusion therapies in time windows that have been originally considered futile or even unsafe. Both systemic and endovascular reperfusion therapies have been shown to improve outcome in patients with wake-up strokes or symptom onset beyond 4.5 h for intravenous thrombolysis and beyond 6 h for endovascular treatment; however, they require advanced neuroimaging to select stroke patients safely. Experts have proposed simpler imaging algorithms but high-quality data on safety and efficacy are currently missing. RCTs used diverse imaging and clinical inclusion criteria for patient selection during the dawn of this novel stroke treatment paradigm. After taking into consideration the dismal prognosis of nonrecanalized ischemic stroke patients and the substantial clinical benefit of reperfusion therapies in selected late presenters, we propose rescue reperfusion therapies for acute ischemic stroke patients not fulfilling all clinical and imaging inclusion criteria as an option in a subgroup of patients with clinical and radiological profiles suggesting low risk for complications, notably hemorrhagic transformation as well as local or remote parenchymal hemorrhage. Incorporating new data to treatment algorithms may seem perplexing to stroke physicians, since treatment and imaging capabilities of each stroke center may dictate diverse treatment pathways. This narrative review will summarize current data that will assist clinicians in the selection of those late presenters that will most likely benefit from acute reperfusion therapies. Different treatment algorithms are provided according to available neuroimaging and endovascular treatment capabilities.

Published
2021
Full Text
View/download PDF

12. Stem Cells as an Emerging Paradigm in Stroke 3

Author

Savitz, Sean I, Cramer, Steven C, Wechsler, Lawrence, Aronowski, Jaroslaw, Boltze, Johannes, Borlongan, Cesar, Case, Casey, Chase, Thomas, Chopp, Michael, Carmichael, S Thomas, Duncan, Pam, Finklestein, Seth, Fischkoff, Steven, Guzman, Raphael, Hess, David C, Huang, David, Hinson, Jim, Kautz, Steven, Kondziolka, Douglas, Mays, Robert, Misra, Vivek, Mitsias, Panos, Modo, Michael, Muir, Keith, Sinden, John, Snyder, Evan, Steinberg, Gary, Vahidy, Farhaan, Willing, Alison, Wolf, Steven, Yankee, Ernest, and Yavagal, Dileep R

Subjects
Biomarkers, Chronic Disease, Clinical Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Endpoint Determination, Humans, Patient Selection, Stem Cell Transplantation, Stem Cells, Stroke, Stroke Rehabilitation, guideline, stem cells, stroke, STEPS 3 Consortium, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Neurosciences, Neurology & Neurosurgery
Published
2014

13. Microbleed prevalence and burden in anticoagulant‐associated intracerebral bleed

Author

Vasileios‐Arsenios Lioutas, Nitin Goyal, Aristeidis H. Katsanos, Christos Krogias, Ramin Zand, Vijay K. Sharma, Panayiotis Varelas, Konark Malhotra, Maurizio Paciaroni, Aboubakar Sharaf, Jason Chang, Odysseas Kargiotis, Abhi Pandhi, Christoph Schroeder, Argyrios Tsantes, Efstathios Boviatsis, Chandan Mehta, Panayiotis D. Mitsias, Magdy H. Selim, Andrei V. Alexandrov, and Georgios Tsivgoulis

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Prior studies suggest an association between Vitamin K antagonists (VKA) and cerebral microbleeds (CMBs); less is known about nonvitamin K oral anticoagulants (NOACs). In this observational study we describe CMB profiles in a multicenter cohort of 89 anticoagulation‐related intracerebral hemorrhage (ICH) patients. CMB prevalence was 51% (52% in VKA‐ICH, 48% in NOAC‐ICH). NOAC‐ICH patients had lower median CMB count [2(IQR:1–3) vs. 7(4–11); P

Published
2019
Full Text
View/download PDF

14. Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature

Author

Stefanos Ioannidis, Michael Mavridis, and Panayiotis D. Mitsias

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Stroke is a frequent occurrence among patients suffering from systemic lupus erythematosus (SLE), but it rarely occurs as the initial manifestation of the disease. We here present the case of a 37 year-old patient who developed an acute cerebellar ischemic stroke as initial event of SLE: elevated partial thromboplastin time and ESR, thrombocytopenia, anti-ds-DNA, anti-SSA, anti-JO-1, and the lupus anticoagulant were detected, and the diagnosis of SLE was established. In addition, we reviewed the literature in order to clarify the demographic, clinical, imaging and outcome characteristics of such a presentation, and found 10 similar cases. Most patients were young (age 31.7 ± 8.5 years) and women (8/11, 72.7%). Stroke most often affected the vertebrobasilar territory (7/11, 63.6%). The stroke mechanism was not clearly defined in these cases. Treatment with immunosuppression and anticoagulation was considered to be a reasonable choice for early secondary stroke prevention. The occurrence of ischemic stroke, primarily in the vertebrobasilar system among young patients, especially women, should always raise suspicion for underlying SLE, and prompt diagnostic investigations to confirm or exclude its presence. Keywords: Ischemic stroke, Systemic lupus erythematosus, Initial manifestation, Stroke in young patient

Published
2018
Full Text
View/download PDF

15. Genetic cause of epilepsy in a Greek cohort of children and young adults with heterogeneous epilepsy syndromes

Author

Ioannis Zaganas, Pelagia Vorgia, Martha Spilioti, Lambros Mathioudakis, Maria Raissaki, Stavroula Ilia, Melpomeni Giorgi, Irene Skoula, Georgios Chinitrakis, Kleita Michaelidou, Evangelos Paraskevoulakos, Olga Grafakou, Chariklia Kariniotaki, Thekla Psyllou, Spiros Zafeiris, Maria Tzardi, George Briassoulis, Argirios Dinopoulos, Panayiotis Mitsias, and Athanasios Evangeliou

Subjects
Epilepsy, Genetics, Whole exome sequencing, Next-generation sequencing, Inherited epilepsy, Neurology. Diseases of the nervous system, RC346-429, Neurophysiology and neuropsychology, QP351-495
Abstract

We describe a cohort of 10 unrelated Greek patients (4 females, 6 males; median age 6.5 years, range 2–18 years) with heterogeneous epilepsy syndromes with a genetic basis. In these patients, causative genetic variants, including two novel ones, were identified in 9 known epilepsy-related genes through whole exome sequencing. A patient with glycine encephalopathy was a compound heterozygote for the p.Arg222Cys and the p.Ser77Leu AMT variant. A patient affected with Lafora disease carried the homozygous p.Arg171His EPM2A variant. A de novo heterozygous variant in the GABRG2 gene (p.Pro282Thr) was found in one patient and a pathogenic variant in the GRIN2B gene (p.Gly820Val) in another patient. Infantile-onset lactic acidosis with seizures was associated with the p.Arg446Ter PDHX gene variant in one patient. In two additional epilepsy patients, the p.Ala1662Val and the novel non-sense p.Phe1330Ter SCN1A gene variants were found. Finally, in 3 patients we observed a novel heterozygous missense variant in SCN2A (p.Ala1874Thr), a heterozygous splice site variant in SLC2A1 (c.517-2A>G), as a cause of Glut1 deficiency syndrome, and a pathogenic variant in STXBP1 (p.Arg292Leu), respectively. In half of our cases (patients with variants in the GRIN2B, SCN1A, SCN2A and SLC2A1 genes), a genetic cause with potential management implications was identified.

Published
2021
Full Text
View/download PDF

16. Genetic cause of heterogeneous inherited myopathies in a cohort of Greek patients

Author

Ioannis Zaganas, Vasilios Mastorodemos, Martha Spilioti, Lambros Mathioudakis, Helen Latsoudis, Kleita Michaelidou, Dimitra Kotzamani, Konstantinos Notas, Konstantinos Dimitrakopoulos, Irene Skoula, Stefanos Ioannidis, Eirini Klothaki, Sophia Erimaki, Georgios Stavropoulos, Vassilios Vassilikos, Georgios Amoiridis, Georgios Efthimiadis, Athanasios Evangeliou, and Panayiotis Mitsias

Subjects
Genetics, Inherited myopathy, Limb-girdle muscular dystrophy, Whole exome sequencing, Genetic diagnosis, Medicine (General), R5-920, Biology (General), QH301-705.5
Abstract

Inherited muscle disorders are caused by pathogenic changes in numerous genes. Herein, we aimed to investigate the etiology of muscle disease in 24 consecutive Greek patients with myopathy suspected to be genetic in origin, based on clinical presentation and laboratory and electrophysiological findings and absence of known acquired causes of myopathy. Of these, 16 patients (8 females, median 24 years-old, range 7 to 67 years-old) were diagnosed by Whole Exome Sequencing as suffering from a specific type of inherited muscle disorder. Specifically, we have identified causative variants in 6 limb-girdle muscular dystrophy genes (6 patients; ANO5, CAPN3, DYSF, ISPD, LAMA2, SGCA), 3 metabolic myopathy genes (4 patients; CPT2, ETFDH, GAA), 1 congenital myotonia gene (1 patient; CLCN1), 1 mitochondrial myopathy gene (1 patient; MT-TE) and 3 other myopathy-associated genes (4 patients; CAV3, LMNA, MYOT). In 6 additional family members affected by myopathy, we reached genetic diagnosis following identification of a causative variant in an index patient. In our patients, genetic diagnosis ended a lengthy diagnostic process and, in the case of Multiple acyl-CoA dehydrogenase deficiency and Pompe’s disease, it enabled specific treatment to be initiated. These results further expand the genotypic and phenotypic spectrum of inherited myopathies.

Published
2020
Full Text
View/download PDF

20. Patent Foramen Ovale in Cryptogenic Ischemic Stroke: Direct Cause, Risk Factor, or Incidental Finding?

Author

Stefanos G. Ioannidis and Panayiotis D. Mitsias

Subjects
ischemic stroke, cryptogenic stroke, patent foramen ovale, atrial septal defect, right-left shunt, paradoxical embolism, Neurology. Diseases of the nervous system, RC346-429
Abstract

Patent foramen ovale (PFO) has been associated with cryptogenic stroke. There is conflicting data and it remains uncertain whether PFO is the direct cause, a risk factor or an incidental finding. Potential stroke mechanisms include paradoxical embolism from a venous clot which traverses the PFO, in situ clot formation within the PFO, and atrial arrhythmias due to electrical signaling disruption. Main risk factors linked with PFO-attributable strokes are young age, PFO size, right-to-left shunt degree, PFO morphology, presence of atrial septal aneurysm, intrinsic coagulation-anticoagulation systems imbalance, and co-existence of other atrial abnormalities, such as right atrial septal pouch, Eustachian valve and Chiari's network. These may act independently or synergistically, multiplying the risk of embolic events. The RoPE score, a scale that includes factors such as young age, cortical infarct location and absence of traditional stroke risk factors, is associated with the probability of a PFO being pathogenic and stroke recurrence risk after the index stroke. Multiple investigators have attempted to correlate other PFO features with the risk of PFO-related stroke, but further investigation is needed before any robust conclusions are reached. PFO presence in young patients with cryptogenic stroke should be considered as etiologically suspect. Caution should be exercised in interpreting the relevance of other PFO features.

Published
2020
Full Text
View/download PDF

21. Whole exome sequencing establishes diagnosis of Charcot–Marie–Tooth 4J, 1C, and X1 subtypes

Author

Kleita Michaelidou, Ioannis Tsiverdis, Sophia Erimaki, Dimitra Papadimitriou, Georgios Amoiridis, Alexandros Papadimitriou, Panayiotis Mitsias, and Ioannis Zaganas

Subjects
Charcot–Marie–Tooth disease, genetics, inherited polyneuropathy, whole exome sequencing, Genetics, QH426-470
Abstract

Abstract Background Charcot–Marie–Tooth (CMT) hereditary polyneuropathies pose a diagnostic challenge. Our aim here is to describe CMT patients diagnosed by whole exome sequencing (WES) following years of fruitless testing. Methods/Results Three patients with polyneuropathy suspected to be genetic in origin, but not harboring PMP22 gene deletion/duplication, were offered WES. The first patient, a 66‐year‐old man, had been suffering from progressive weakness and atrophies in the lower and upper extremities for 20 years. Due to ambiguous electrophysiological findings, immune therapies were administered to no avail. Twelve years after PMP22 deletion/duplication testing, WES revealed two pathogenic variants in the FIG4 gene (p.Ile41Thr and p.Phe598fs, respectively), as a cause of CMT 4J. The second patient, a 19‐year‐old man, had been suffering from hearing and gait impairment since at least his infancy, and recently presented with weakness and dystonia of the lower extremities. In this patient, WES identified the p.Leu122Val LITAF gene variant in heterozygous state, suggesting the diagnosis of CMT 1C, several years after initial genetic analyses. The third patient, a 44‐year‐old man, presented with progressive weakness and atrophies of the lower and upper extremities since the age of 17 years old. In this patient, WES identified the hemizygous p.Arg164Gln pathogenic variant in the GJB1 gene, establishing the diagnosis of CMT X1, 8 years after testing for PMP22 deletion/duplication. Conclusion Novel diagnostic techniques, such as WES, offer the possibility to decipher the cause of CMT subtypes, ending the diagnostic Odyssey of the patients and sparing them from unnecessary and potentially harmful treatments.

Published
2020
Full Text
View/download PDF

25. Abstracts from the Food Allergy and Anaphylaxis Meeting 2016

Author

Guillaume Pouessel, Claire Claverie, Julien Labreuche, Jean-Marie Renaudin, Aimée Dorkenoo, Mireille Eb, Anne Moneret-Vautrin, Antoine Deschildre, Stephane Leteurtre, Linus Grabenhenrich, Margitta Worm, Sabine Dölle, Kathrin Scherer, Isidor Hutteger, Morten Christensen, Carsten Bindslev-Jensen, Charlotte Mortz, Esben Eller, Henrik Fomsgaard Kjaer, Leonor Carneiro-Leão, Jenny Badas, Alice Coimbra, Dikla Pivko Levy, Moshe Ben-Shoshan, Ayelet Rimon, Shira Benor, Nicolette J. T. Arends, Nikki Edelbroek, Hans de Groot, Joyce A. M. Emons, H. Kim A. Brand, Dirk Verhoeven, Leonieke N. van Veen, Nicolette W. de Jong, Geunwoong Noh, Eun Ha Jang, Mariona Pascal, Olga Dominguez, Mònica Piquer, Montserrat Alvaro, Rosa Jimenez-Feijoo, Jaime Lozano, Adriana Machinena, Maria del Mar Folqué, Maria Teresa Giner, Ana María Plaza, Paul Turner, Nandinee Patel, Marta Vazquez-Ortiz, Sarah Lindsley, Lucy Walker, Simon Rosenberg, Adriano Mari, Claudia Alessandri, Ivana Giangrieco, Lisa Tuppo, Chiara Rafaiani, Georg Mitterer, Michela Ciancamerla, Rosetta Ferrara, Maria Livia Bernardi, Danila Zennaro, Maurizio Tamburrini, Maria Antonetta Ciardiello, Christian Harwanegg, Antonio Fernandez, Regina Selb, Philippe Egenmann, Michelle Epstein, Karin Hoffmann-Sommergruber, Frits Koning, Martinus Lovik, E. N. Clare Mills, Javier Moreno, Henk van Loveren, Jean-Michel Wal, Susanne Diesner, Cornelia Bergmayr, Barbara Pfitzner, Vera Elisabeth Assmann, Philipp Starkl, David Endesfelder, Thomas Eiwegger, Zsolt Szepfalusi, Heinz Fehrenbach, Erika Jensen-Jarolim, Anton Hartmann, Isabella Pali-Schöll, Eva Untersmayr, Soren Wille, Peter Meyer, Caroline Klingebiel, Jonas Lidholm, Angelica Ehrenberg, Jonas Östling, Isabelle Cleach, Jean-Louis Mège, Joana Vitte, Roberta Aina, Pawel Dubiela, Sabine Pfeifer, Merima Bublin, Christian Radauer, Piotr Humeniuk, Stefan Kabasser, Riccardo Asero, Gador Bogas, Francisca Gomez, Paloma Campo, Maria Salas, Inmaculada Doña, Esther Barrionuevo, Maria Auxiliadora Guerrero, Cristobalina Mayorga, Ana Prieto, Domingo Barber, Maria Jose Torres, Annette Jamin, Andrea Wangorsch, Barbara Ballmer, Stefan Vieths, Stephan Scheurer, Danijela Apostolovic, Jelena Mihailovic, Maja Krstic, Maria Starkhammar, Tanja Cirkovic Velickovic, Carl Hamsten, Marianne van Hage, Francine C. van Erp, Edward F. Knol, Hannah M. Kansen, Bo Pontoppidan, Yolanda Meijer, Cornelis K. van der Ent, André C. Knulst, Rebekah Sayers, Helen Brown, Adnan Custovic, Angela Simpson, Claire Mills, Juliane Schulz, Network for Online Registration of Anaphylaxis (NORA), Jaap Akkerdaas, Muriel Totis, Annabelle Capt, Corinne Herouet-Guicheney, Ronald van Ree, Tushar Banerjee, Antima Banerjee, Mathilde Claude, Grégory Bouchaud, Roberta Lupi, Laure Castan, Olivier Tranquet, Sandra Denery-Papini, Marie Bodinier, Chantal Brossard, Rosella De Poi, Elisa Gritti, Emiliano De Dominicis, Bert Popping, Patrizia Polverino de Laureto, Kati Palosuo, Anna Kaarina Kukkonen, Anna Pelkonen, Mika Mäkelä, Nanju Alice Lee, Johanna Rost, Sridevi Muralidharan, Dianne Campbell, Sam Mehr, Catherine Nock, Joseph Baumert, Steve Taylor, Carla Mastrorilli, Salvatore Tripodi, Carlo Caffarelli, Serena Perna, Andrea Di Rienzo Businco, Ifigenia Sfika, Arianna Dondi, Annamaria Bianchi, Carlotta Povesi Dascola, Giampaolo Ricci, Francesca Cipriani, Nunzia Maiello, Michele Miraglia del Giudice, Tullio Frediani, Simone Frediani, Francesco Macrì, Chiara Pistoletti, Iride Dello Iacono, Maria Francesca Patria, Elena Varin, Diego Peroni, Pasquale Comberiati, Loredana Chini, Viviana Moschese, Sandra Lucarelli, Roberto Bernardini, Giuseppe Pingitore, Umberto Pelosi, Roberta Olcese, Matteo Moretti, Anastasia Cirisano, Diego Faggian, Alessandro Travaglini, Mario Plebani, Maria Carmen Verga, Mauro Calvani, Paolo Giordani, Paolo Maria Matricardi, Noe Ontiveros, Francisco Cabrera-Chavez, Julie Galand, Etienne Beaudouin, The Anaphylaxis Working Group of the French Allergology SocietyThe Anaphylaxis Working Group of the French Allergology Society, Florence Pineau, Shinobu Sakai, Kayoko Matsunaga, Reiko Teshima, Colette Larré, Sandra Denery, Sebastian Tschirner, Valérie Trendelenburg, Gabriele Schulz, Bodo Niggemann, Kirsten Beyer, Youcef Bouferkas, Younes Belabbas, Djamel Saidi, Omar Kheroua, Kamel Eddine El Mecherfi, Malika Guendouz, Abir Haddi, Hanane Kaddouri, Luis Amaral, Ana Pereira, Susana Rodrigues, Mareen Datema, Laurian Jongejan, Michael Clausen, Andre Knulst, Nikolaos Papadopoulos, Marek Kowalski, Frédéric de Blay, Aeilko Zwinderman, Karin Hoffman-Sommergruber, Barbara Ballmer-Weber, Montserrat Fernandez-Rivas, Shan Deng, Jia Yin, Charlotte Eisenmann, Maria Nassiri, Rabea Reinert, Johanna P. M. van der Valk, Roy Gerth van Wijk, Yvonne Vergouwe, Ewout W. Steyerberg, Marit Reitsma, Harry J. Wichers, Huub F. J. Savelkoul, Berber Vlieg-Boerstra, Anthony E. J. Dubois, Fabrícia Carolino, Ana Rodolfo, Josefina Cernadas, Dasha Roa-Medellín, Ana Rodriguez-Fernandez, Joaquín Navarro, Vicente Albendiz, María Luisa Baeza, Sonsoles Intente-Herrero, Andrea Mikkelsen, Kirsten Mehlig, Lauren Lissner, Linda Verrill, Stefano Luccioli, Jolanda van Bilsen, Frieke Kuper, André Wolterbeek, Tanja Rouhani Rankouhi, Lars Verschuren, Hilde Cnossen, Prescilla Jeurink, Johan Garssen, Léon Knippels, Jossie Garthoff, Geert Houben, Winfried Leeman, M. Eleonore Pettersson, Afke M. M. Schins, Gerard H. Koppelman, Boudewjin J. Kollen, Svitlana Zubchenko, Sarah Kuntz, Pablo Mérida, Montserrat Álvaro, Monica Piquer, Carmen Riggioni, Juan Heber Castellanos, Rosa Jimenez, Melanie Cap, Elodie Drumez, Stéphanie Lejeune, Caroline Thumerelle, Clémence Mordacq, Véronique Nève, Sonia Ricò, Margherita Varini, Rita Nocerino, Linda Cosenza, Antonio Amoroso, Margherita Di Costanzo, Carmen Di Scala, Giorgio Bedogni, Roberto Berni Canani, Paul J. Turner, Paloma Poza-Guedes, Ruperto González-Pérez, Inmaculada Sánchez-Machín, Victor Matheu-Delgado, Erik Wambre, Anne-Sofie Ballegaard, Charlotte Madsen, Juliane Gregersen, Katrine Lindholm Bøgh, Philippe Aubert, Michel Neunlist, Antoine Magnan, Daniel Lozano-Ojalvo, Alba Pablos-Tanarro, Leticia Pérez-Rodríguez, Elena Molina, Rosina López-Fandiño, Akila Rekima, Patricia Macchiaverni, Mathilde Turfkruyer, Sebastien Holvoet, Lénaïck Dupuis, Nour Baiz, Isabella Annesi-Maesano, Annick Mercenier, Sophie Nutten, Valérie Verhasselt, Ines Mrakovcic-Sutic, Srdan Banac, Ivana Sutic, Zdenka Baricev-Novakovic, Ingrid Sutic, Valentino Pavisic, Rosa Muñoz-Cano, Teodoríkez Jiménez-Rodríguez, Daniel Corbacho, Jordi Roca-Ferrer, Joan Bartra, Aleksandar Bulog, Vladimir Micovic, Lidia Markiewicz, Agata Szymkiewicz, Anna Szyc, Barbara Wróblewska, Bryan M. Harvey, Lucien F. Harthoorn, A. Wesley Burks, Georgios Rentzos, Anna-Lena Bramstång Björk, Ulf Bengtsson, Colin Barber, Chrystyna Kalicinsky, Christine Breynaert, Lieve Coorevits, Cornelia Jansen, Erna Van Hoeyveld, Kristin Verbeke, Anne-Marie Kochuyt, Rik Schrijvers, Diana Deleanu, Adriana Muntean, Maria Konstantakopoulou, Maria Pasioti, Anastasia Papadopoulou, Anna Iliopoulou, Nikolaos Mikos, Evangelia Kompoti, Eunice Dias de Castro, Borja Bartalomé, Kok Loong Ue, Elizabeth Griffiths, Stephen Till, Kate Grimshaw, Graham Roberts, Anna Selby, Indre Butiene, Jose Ignacio Larco, Ruta Dubakiene, Ana Fiandor, Alessandro Fiocchi, Nikos Papadopoulos, Sigurveig Sigurdardottir, Aline Sprikkelman, Anne-Fleur Schoemaker, Paraskevi Xepapadaki, Thomas Keil, Zizi Cojocariu, Beatriz Secades Barbado, Vasti Iancu, Esozia Arroabarren, Marta Goñi Esarte, Miren Arteaga, Mayra Coutinho Andrade, Denise Borges, Jorge Kalil, Pedro Giavina Bianchi, Rosana Camara Agondi, Rinkesh Kumar Gupta, Akanksha Sharma, Kriti Gupta, Mukul Das, Premendra Dwivedi, Rusudan Karseladze, Liana Jorjoliani, Lali Saginadze, Mariam Tskhakaia, Katia Basello, Gabriele Piuri, Attilio Francesco Speciani, Michela Carola Speciani, Carla Camerotto, Francesco Zinno, Olga Pakholchuk, Svitlana Nedelska, Stefano Pattini, Maria Teresa Costantino, Silvia Peveri, Danilo Villalta, Eleonora Savi, Andrea Costanzi, Vera A. Revyakina, Marina A. Kiseleva, Elena D. Kuvshinova, Inna A. Larkova, Anton A. Shekhetov, Diana Silva, André Moreira, José Plácido, Hanneke van der Kleij, Esther van Twuijver, Robbert Sutorius, Pieter-Jan de Kam, Jenny van Odijk, Helen Lindqvist, Elin Lustig, Amyra Ali Azamar Jácome, Karla Leversia Borjas Aguilar, Miguel García Domínguez, David Alejandro Mendoza Hernández, Cristiano Caruso, Cono Casale, Gian Lodovico Rapaccini, Antonino Romano, Italo De Vitis, Renata R. Cocco, Carolina Aranda, Marcia C. Mallozi, Jackeline F. Motta, Lilian Moraes, Antonio Pastorino, Nelson Rosario, Ekaterini Goudouris, Arnaldo Porto, Neusa F. Wandalsen, Emanuel Sarinho, Flavio Sano, Dirceu Solé, Constantinos Pitsios, Maria Petrodimopoulou, Ekaterini Papadopoulou, Maria Passioti, Meropi Kontogianni, Nino Adamia, Ekaterina Khaleva, Ana Prieto del Prado, George Du Toit, Edyta Krzych, Urszula Samolinska-Zawisza, Konrad Furmanczyk, Aneta Tomaszewska, Filip Raciborski, Agnieszka Lipiec, Piotr Samel-Kowalik, Artur Walkiewicz, Jacek Borowicz, Boleslaw Samolinski, Aimee Lou Nano, Marysia Recto, Maria Luisa Somoza, Natalia Blanca López, Diana Pérez Alzate, Francisco Javier Ruano, Maria Isabel Garcimartín, Elisa Haroun, Maria Vázquez de la Torre, Antonia Rojas, Montserrat López Onieva, Gabriela Canto, Alexandra Rodrigues, Andreia Forno, António Jorge Cabral, Rute Gonçalves, Ilya Vorozhko, Tatyana Sentsova, Olga Chernyak, Svetlana Denisova, Lidia Ilènko, Valery Muhortnich, Caroline Zimmermann, Alexander Rohrbach, Faisal R. Bakhsh, Kollen Boudewijn, Anne-Marie Oomkes-Pilon, Dorien Van Ginkle, Mira Šilar, Anja Jeverica, Tina Vesel, Tadej Avčin, Peter Korošec, Johanna van der Valk, Irene Berends, Nicolette Arends, Maurits van Maaren, Harry Wichers, Joyce Emons, Anthony Dubois, Nicolette de Jong, Oksana Matsyura, Lesya Besh, Chung-Hsiung Huang, Tong-Rong Jan, Gary Stiefel, Jean Tratt, Kerrie Kirk, Fabricia Carolino, Stefania Arasi, Lucia Caminiti, Giuseppe Crisafulli, Chiara Fiamingo, Jlenia Fresta, Giovanni Pajno, Ben Remington, Astrid Kruizinga, W. Marty Blom, Joost Westerhout, Sabina Bijlsma, Joe Baumert, Mark Blankestijn, Henny Otten, Rob Klemans, Anouska D. Michelsen-Huisman, Harmieke van Os-Medendorp, Astrid G. Kruizinga, Astrid Versluis, Gert van Duijn, H. Mary-Lene de Zeeuw-Brouwer, Jacqueline J. M. Castenmiller, Hub P. J. M. Noteborn, Geert F. Houben, Kristian Bravin, David Luyt, Bushra Javed, Phil Couch, Christopher Munro, Phil Padfield, Matt Sperrin, Aideen Byrne, Lizalet Oosthuizen, Carina Kelleher, Fiona Ward, Niamh Brosnan, Graham King, Eva Corbet, Josué Alejandro Huertas Guzmán, Montserrat Bosque García, Oscar Asensio, Laura Valdesoiro Navarrete, Helena Larramona, Xavier Domingo Miró, Katarzyna Pyrz, Moira Austin, Yanne Boloh, Philip Couch, Deirdre Galloway, Pilar Hernandez, Jonathan O’B. Hourihane, Fiona Kenna, Barbara Majkowska-Wojciechowska, Lynne Regent, Marina Themisb, Sabine Schnadt, Aida Semic-Jusufagic, Audrey Dunn Galvin, Tiina Kauppila, Mikael Kuitunen, Nikolaos A. Kitsioulis, Nikolaos Douladiris, Sofia Kostoudi, Ioanna Manolaraki, Dimitris Mitsias, Emmanouil Manousakis, Nikolaos G. Papadopoulos, Rebecca Knibb, Jennifer Hammond, Richard Cooke, Jaakko Yrjänä, Anna-Maija Hanni, Päivi Vähäsarja, Oona Mustonen, Teija Dunder, Petri Kulmala, Eva Lasa, Carmen D’Amelio, Sara Martínez, Alejandro Joral, Gabriel Gastaminza, Maria Jose Goikoetxea, David C. A. Candy, Marleen T. J. Van Ampting, Manon M. Oude Nijhuis, Assad M. Butt, Diego G. Peroni, Adam T. Fox, Jan Knol, Louise J. Michaelis, Ines Padua, Patricia Padrao, Pedro Moreira, Renata Barros, Hanan Sharif, Manzoor Ahmed, Nehad Gomaa, Joris Mens, Koen Smit, Frans Timmermans, Tomaž Poredoš, Anja Koren Jeverica, Marjeta Sedmak, Evgen Benedik, Meta Accetto, Mirjana Zupančič, Glauce Yonamine, Gustavo Soldateli, Bruna Aquilante, Antonio Carlos Pastorino, Cleonir Lui de Moraes Beck, Andrea Keiko Gushken, Mayra de Barros Dorna, Cristiane Nunes dos Santos, Ana Paula Moschione Castro, Abdulhadi Al-Qahtani, Rand Arnaout, Agha Rehan Khaliq, Rashid Amin, Farrukh Sheikh, Jorge Alvarez, Marta Anda, Miriam Palacios, Montserrat De Prada, Carmen Ponce, Bianca Balbino, Riccardo Sibilano, Thomas Marichal, Nicolas Gaudenzio, Hajime Karasuyama, Pierre Bruhns, Mindy Tsai, Laurent L. Reber, Stephen J. Galli, Ana Reis Ferreira, Josefina R. Cernadas, Aida del Campo García, Sara Pereiro Fernández, Nerea Sarmiento Carrera, Fernando Bandrés Sánchez-Cruz, José Ramón Fernández Lorenzo, Stephanie Claus, Claudia Pföhler, Franziska Ruëff, Regina Treudler, Mercedes Escarrer Jaume, Agustin Madroñero, Maria Teresa Guerra Perez, Juan Carlos Julia, Charlotte Hands Plovdiv, Lee Gethings, Jim Langridge, Karine Adel-Patient, Hervé Bernard, Ivona Barcievic-Jones, Raditsa Sokolova, Rumyana Yankova, Mariya Ivanovska, Marianna Murdjeva, Tatyana Popova, Svetlan Dermendzhiev, Martin Karjalainen, Ulrike Lehnigk, Duncan Brown, Julie C. Locklear, Julie Locklear, Ioana Maris, Jonathan Hourihane, Cristina Ornelas, Joana Caiado, Manuel Branco Ferreira, Manuel Pereira-Barbosa, Yolanda Puente, Juan Carlos Daza, Francisco Javier Monteseirin, Natalia Ukleja-Sokolowska, Ewa Gawronska-Ukleja, Magdalena Zbikowska-Gotz, Zbigniew Bartuzi, Lukasz Sokolowski, Aine Adams, Bernard Mahon, Karen English, Nelly Gourdon-Dubois, Laetitia Sellam, Bruno Pereira, Elodie Michaud, Khaled Messaoudi, Bertrand Evrard, Jean-Luc Fauquert, Francisca Palomares, Gador Gomez, Maria Jose Rodriguez, Luisa Galindo, Ana Molina, Lorella Paparo, Maurizio Mennini, Rosita Aitoro, Adam Wawrzeńczyk, Michał Przybyszewski, Anna Wawrzeńczyk, Hulya Ercan Sarıcoban, Meltem Ugras, Zerrin Yalvac, Bertine M. J. Flokstra-de Blok, J. L. van der Velde, Andrea Vereda, Clara Ippolito, Amaranta Traversa, Daniela Adriano, Daniela Manila Bianchi, Silvia Gallina, Lucia Decastelli, Melina Makatsori, Anne Miles, Sonja Posega Devetak, Iztok Devetak, Soraya Ainad Tabet, Jeanette Fisker Trandbohus, Pernille Winther, Hans-Jørgen Malling, Kirsten Skamstrup Hansen, Lene Heise Garvey, Chia-Chi Wang, Yin-Hua Cheng, Chun-Wei Tung, Mariola Dietrich, Ingo Marenholz, Birgit Kalb, Sarah Grosche, Katharina Blümchen, Rupert Schlags, Mareike Price, Sylke Rietz, Jorge Esparza-Gordillo, Susanne Lau, Young-Ae Lee, Ali Almontasheri, Mohammad Al Bahkali, Sahar Elshorbagi, Abdullah Alfhaid, Mashary Altamimi, Eman Madbouly, Hassan Al-Dhekri, Rand K. Arnaout, Maria Basagaña, Sira Miquel, Borja Bartolomé, Bettina Brix, Stefanie Rohwer, Sandra Brandhoff, Alena Berger, Waltraud Suer, Alf Weimann, Cristina Bueno, Laura Martín-Pedraza, Sara Abián, Pablo San Segundo-Acosta, Juan Carlos López-Rodríguez, Rodrigo Barderas, Eva Batanero, Javier Cuesta-Herranz, María Teresa Villalba, Magna Correia, Filipe Benito-Garcia, Cristina Arêde, Susana Piedade, Mário Morais-Almeida, James Hindley, Ross Yarham, Anna Kuklinska-Pijanka, David Gillick, Karine Patient, Martin D. Chapman, Katrine L. Bøgh, Ana Miranda, Eugénia Matos, Anna Sokolova, Huan Rao, Ivona Baricevic-Jones, Frances Smith, Wentong Xue, Helga Magnusdottir, Anna G. Vidarsdottir, Sigrun Lund, Anders Blom Jensen, Bjorn R. Ludviksson, Reyna Simon, Robert Elfont, Sean Bennett, Robert Voyksner, Maria de Lurdes Torre, Songül Yürek, Margaretha A. Faber, Annick Bastiaensen, Evelyne Mangodt, Athina van Gasse, Ine Decuyper, Vito Sabato, Margo M. Hagendorens, Chris H. Bridts, Luc S. De Clerck, Didier Ebo, Susanne Schwarz, Mandy Ziegert, Saskia Albroscheit, Christian Schwager, Skadi Kull, Jochen Behrends, Niels Röckendorf, Frauke Schocker, Andreas Frey, Arne Homann, Wolf-Meinhard Becker, Uta Jappe, Nesrine Zaabat, Sylvia Osscini, Chantal Agabriel, Benoît Sterling, Ania Carsin, Valérie Liabeuf, Monica Maćków, Alina Zbróg, Monica Bronkowska, Justine Courtois, Romy Gadisseur, Catherine Bertholet, Pierre Lukas, Etienne Cavalier, Philippe Delahaut, Birgit Quinting, Margareta Brandt Gertmo, Ewa Ternesten Hasseus, Vladyslava Barzylovych, Júlio Oliveira, Luis F. Ensina, Carolina S. Aranda, Leire Dopazo, Rebeca Lopez, Raquel Perez, Laura Santos-Diez, Agurtzane Bilbao, Juan Miguel Garcia, Ignacio García Núñez, María Ángeles Algaba Mármol, María José Barasona Villarejo, José Antonio Bácter Martos, Marina Suárez Vergara, José María Ignacio García, Agata Michalska, Grzegorz Sergiejko, Robert Zacniewski, Ileana-Maria Ghiordanescu, Cristina Deaconu, Mihaela Popescu, Roxana Silvia Bumbacea, Alkerta Ibranji, Elida Nikolla, Gjustina Loloci, Nanna Juel-Berg, Lau Fabricius Larsen, Lars Kjaergaard Poulsen, João Marcelino, Ricardo Prata, Ana Célia Costa, Fátima Duarte, Marta Neto, Jennifer Santos, Luís Câmara Pestana, Daniel Sampaio, Paola Minale, Paola Dignetti, Donatella Bignardi, Irena Nedelea, Florin-Dan Popescu, Mariana Vieru, Florin-Adrian Secureanu, Carmen Saviana Ganea, Miguel Vieira, José Pedro Moreira Silva, Timothy Watts, Sophia Watts, Marta Lomikovska, Marina Peredelskaya, Natalia Nenasheva, Ivana Filipovic, Zorica Zivkovic, Djordje Filipovic, Jennette Higgs, Amena Warner, and Carla Jones

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2017
Full Text
View/download PDF

29. Intravenous thrombolysis for acute ischemic stroke in Greece: the Safe Implementation of Thrombolysis in Stroke registry 15-year experience

Author

Georgios Tsivgoulis, Odysseas Kargiotis, Jobst Rudolf, Apostolos Komnos, Antonios Tavernarakis, Theodoros Karapanayiotides, John Ellul, Aristeidis H. Katsanos, Sotirios Giannopoulos, Maria Gryllia, Apostolos Safouris, Panagiotis Papamichalis, Konstantinos Vadikolias, Panayiotis Mitsias, and Georgios Hadjigeorgiou

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Background: Intravenous thrombolysis (IVT) remains the only approved systemic reperfusion treatment for acute ischemic stroke (AIS), however there are scarce data regarding outcomes and complications of IVT in Greece. We evaluated safety and efficacy outcomes of IVT for AIS in Greece using the Safe Implementation of Thrombolysis in Stroke: International Stroke Thrombolysis Register (SITS-ISTR) dataset. Methods: All AIS patients treated with IVT in Greece between December 2002 and July 2017 and recorded in the SITS-ISTR were evaluated. Demographics, risk factors, baseline stroke severity [defined using National Institutes of Health Stroke Scale (NIHSS)], and onset-to-treatment time (OTT) were recorded. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and 3-month mortality rates. The efficacy outcomes evaluated a reduction in baseline NIHSS score at 2 and 24 h following IVT onset, 3-month favorable functional outcome [FFO; modified Rankin scale (mRS) scores of 0–1] and 3-month functional independence (FI; mRS-scores of 0–2). The safety and efficacy outcomes were assessed comparatively with previously published data from SITS national and international registries. Results: A total of 523 AIS patients were treated with IVT in 12 Greek centers participating in the SITS-ISTR during the study period (mean age 62.4 ± 12.7; 34.6% women; median baseline NIHSS score: 11 points; median OTT: 150 min). The rates of sICH were 1.4%, 2.3%, and 3.8% according to the SIST-MOST, ECASS II, and NINDS criteria respectively. The median reduction in NIHSS score at 2 and 24 h was 3 [interquartile range (IQR): 1–5] and 5 (IQR: 2–8) points respectively. The 3-month FI, FFO and mortality were 66.5%, 55.6% and 7.9%. All safety and efficacy outcomes were comparable with available data from SITS-ISTR in other European countries. Conclusions: Our study underscores the safety and efficacy of IVT for AIS in Greece. Additional action is necessary in order to increase the availability of IVT in the Greek population and to include more centers in the SITS-ISTR.

Published
2018
Full Text
View/download PDF

30. Delivery of acute ischaemic stroke treatments in the European region in 2019 and 2020

Author

Aguiar de Sousa, Diana, Wilkie, Arlene, Norrving, Bo, Macey, Chris, Bassetti, Claudio, Tiu, Cristina, Roth, Greg, Lunde, Grethe, Christensen, Hanne, Fiehler, Jens, Pezzella, Francesca Romana, Dichgans, Martin, Roaldsen, Melinda B, Kelly, Peter, Mikulik, Robert, Sacco, Simona, Caso, Valeria, Fischer, Urs, Basha, Entela, Yeghiazaryan, Nune, Kiechl, Stefan, Shiraliyeva, Rana, Vanacker, Peter, Bender, Marija, Emilov Tsalta-Mladenov, Mihael, Budincevic, Hrvoje, Tomek, Ales, Kaponides, Georgios, Klingenberg Iversen, Helle, Faiss, Jürgen, Kõrv, Janika, Sairanen, Tiina, Igor, Sibon, Tsiskaridze, Alexander, Ntaios, George, Tsivgoulis, Georgios, Szapary, Laszlo, Logi Thorarinsson, Bjorn, Harbison, Joe, Bornstein, Natan M., Toni, Danilo, Fisnik, Jashari, Karbozova, Kunduz, Miglane, Evija, Dalius, Jatužis, Droste, Dirk, Mallia, Maria, Jevto, Erakovic, Arsovska, Anita, Fromm, Annette, Kobayashi, Adam, Azevedo, Elsa, Groppa, Stanislav, Cristina, Tiu, Guekht, Alla, Zivanovic, Zeljko, Nosal, Vladimir, Zvan, Bojana, López-Cancio, Elena, Pérez de la Ossa, Natàlia, Norrving, Bo, Nedeltchev, Krassen, Vrijhoef, Bert, Akif Topcuoglu, Mehmet, Flomin, Yuriy, Ahmed, Rubina, Shelesko, Andrey, Petrela, Mentor, Zubalova, Lina, Hasanov, Rovshan, Raedt, Sylvie De, Nevena, Mahmutbegović, Peteva Andonova, Silva, Poljakovic, Zdravka, Skoda, Ondrej, Søren Paaske, Johnsen, med. Helmuth Steinmetz, Prof. Dr., Kõrv, Janika, Sairanen, Tiina, Denis, Sablot, Lobjanidze, Nino, Milionis, Haralambos, Mitsias, Panagiotis, Tarkanyi MD, Gabor, Elisabeth Klinke, Marianne, Tanne, David, Luca, Petraglia, Dren, Boshnjaku, Turgumbaev, Dzhamal, Guntis, Karelis, Dalius, Jatužis, Droste, Dirk, Mladen, Debeljevic, Arsovska, Anita, Kurz, Martin, Anna, Czlonkowska, Eremei, Zota, Elena Oana, Terecoasa, Martinov, Mikhail, Jovanović, Dejana, Gdovinova, Zuzana, Zvan, Bojana, López-Cancio, Elena, Camps Renom, Pol, Kwa, Vincent, Murat Arsava, Ethem, Gulyayeva, Maryna, Dharmasiri, Michelle, Basha, Entela, Korompoki, Eleni, Vadikolias, Konstantinos, Bereczki MD, Daniel, Bryndis Einarsdottir, Anna, Afrim, Blyta, Mamytova, Elmira, Kristaps, Jurjans, Daiva, Rastenytė, Costache, Oana, Milovan, Roganovic, Fromm, Annette, Michal, Karlinski, Alexandru, Gasnas, Sorin, Tuta, Fidler, Mikhail, Raičević, Ranko, Zaletel, Marjan, Castellanos, Mar, Gómez-Choco, Manuel, Sirin, Hadiye, Lebedynets, Dmytro, Khaira, Jattinder, Enesi, Eugen, Sahakyan, David, Mammadbayli, Ayten, Lemmens, Robin, Dževdet, Smajlović, Emilov Tsalta-Mladenov, Mihael, Budincevic, Hrvoje, Sramek, Martin, Nabavi, med. Darius, Vibo, Riina, Strbian, Daniel, Aliyev, Rahim, Mikulik, Robert, Ozretic, David, Rocek, Miloslav, Trine, Stavngaard, med. Claus Zimmer, Prof. Dr., Malikov, Vladislav, Lappalainen, Kimmo, Jerome, Berge, Khinikadze, Mirza, Brountzos, Elias, Vilmarsson, Vilhjalmur, Karlis, Kupcs, Marius, Kurminas, Hoffmann, Michel, Grech, Reuben, Marija, Mitric, Kjellevold Wathle, Gaute, Wojciech, Poncyljusz, Igor, Crivorucica, Bogdan, Dorobat, Till, Viktor, Klepanec, Andrej, Milosevic, Zoran, Macho, Juan, Ozdemir, Ozcan, Shchehlov, Dmytro, Dorte, Damgaard, Hermanek, Peter, Sturua, Lela, Siskou, Olga, Tsivgoulis, Georgios, Libruder, Carmit, Indredavik, Bent, Azevedo, Elsa, Elena, Manole, Mijajlović, Milija, Turcani, Peter, Norrving, Bo, Bonati, Leo, Nederkoorn, Paul, Ertuğrul Eğin, Muhammed, Samofalov, Dmytro, Diana, Ose, Rita, Gaidelytė, and Droste, Dirk

Abstract

Introduction: We assessed best available data on access and delivery of acute stroke unit (SU) care, intravenous thrombolysis (IVT) and endovascular treatment (EVT) in the European region in 2019 and 2020.Patients and methods: We compared national data per number of inhabitants and per 100 annual incident first-ever ischaemic strokes (AIIS) in 46 countries. Population estimates and ischaemic stroke incidence were based on United Nations data and the Global Burden of Disease Report 2019, respectively.Results: The estimated mean number of acute SUs in 2019 was 3.68 (95% CI: 2.90–4.45) per one million inhabitants (MIH) with 7/44 countries having less than one SU per one MIH. The estimated mean annual number of IVTs was 21.03 (95% CI: 15.63–26.43) per 100,000 and 17.14% (95% CI: 12.98–21.30) of the AIIS in 2019, with highest country rates at 79.19 and 52.66%, respectively, and 15 countries delivering less than 10 IVT per 100,000. The estimated mean annual number of EVTs in 2019 was 7.87 (95% CI: 5.96–9.77) per 100,000 and 6.91% (95% CI: 5.15–8.67) of AIIS, with 11 countries delivering less than 1.5 EVT per 100,000. Rates of SUs, IVT and EVT were stable in 2020. There was an increase in mean rates of SUs, IVT and EVT compared to similar data from 2016.Conclusion: Although there was an increase in reperfusion treatment rates in many countries between 2016 and 2019, this was halted in 2020. There are persistent major inequalities in acute stroke treatment in the European region. Tailored strategies directed to the most vulnerable regions should be prioritised.

Published
2023
Full Text
View/download PDF

31. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics

Author

Artemiy S. Silantyev, Luca Falzone, Massimo Libra, Olga I. Gurina, Karina Sh. Kardashova, Taxiarchis K. Nikolouzakis, Alexander E. Nosyrev, Christopher W. Sutton, Panayiotis D. Mitsias, and Aristides Tsatsakis

Subjects
molecular biology, proteomics, metabolomics, glioblastoma, mass spectrometry, biomarkers, miRNAs, DNA, proteins, Cytology, QH573-671
Abstract

Glioblastoma multiforme is the most aggressive malignant tumor of the central nervous system. Due to the absence of effective pharmacological and surgical treatments, the identification of early diagnostic and prognostic biomarkers is of key importance to improve the survival rate of patients and to develop new personalized treatments. On these bases, the aim of this review article is to summarize the current knowledge regarding the application of molecular biology and proteomics techniques for the identification of novel biomarkers through the analysis of different biological samples obtained from glioblastoma patients, including DNA, microRNAs, proteins, small molecules, circulating tumor cells, extracellular vesicles, etc. Both benefits and pitfalls of molecular biology and proteomics analyses are discussed, including the different mass spectrometry-based analytical techniques, highlighting how these investigation strategies are powerful tools to study the biology of glioblastoma, as well as to develop advanced methods for the management of this pathology.

Published
2019
Full Text
View/download PDF

32. Editorial: Understanding PFO-associated stroke.

Author

Karapanayiotides T, Lioutas VA, Rubiera M, Montalescot G, and Mitsias P

Abstract

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Published
2023
Full Text
View/download PDF

33. Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis

Author

Georgios Tsivgoulis, Aristeidis H. Katsanos, Georgios Magoufis, Odysseas Kargiotis, Georgios Papadimitropoulos, Konstantinos Vadikolias, Theodoros Karapanayiotides, John Ellul, Anne W. Alexandrov, Panayiotis D. Mitsias, and Andrei V. Alexandrov

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Objectives: The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. Methods: We conducted a systematic review and random effects meta-analysis of all available randomized controlled trials (RCTs) evaluating the safety and efficacy of PTAS (in comparison with medical therapy) for sICAS. Results: Three RCTs (678 total patients) were included in the quantitative analysis. PTAS was associated with a higher risk of recurrent ischemic stroke in the territory of qualifying artery both within 30 days [risk ratio (RR) = 2.21, 95% confidence interval (CI) 1.10–4.43] and 1 year (RR = 1.92, 95% CI 1.10–3.36). PTAS was also related to a higher risk of any ischemic stroke within 30 days from the index event (RR = 2.08, 95% CI 1.17–3.71). The risk for intracranial hemorrhage was found to be higher in PTAS patients both within 30 days (RR = 10.60, 95% CI 1.98–56.62) and 1 year (RR = 8.15, 95% CI 1.50–44.34). The composite outcome of any stroke or death within 1 year (RR = 2.29, 95% CI 1.13–4.66) and 2 years (RR = 1.52, 95% CI 1.04–2.21) was higher in PTAS than in medical therapy. PTAS was associated with a higher risk of any stroke or death within 2 years in the sICAS subgroup located in posterior circulation (RR = 2.37, 95% CI 1.27–4.42). Conclusions: PTAS is associated with adverse early and long-term outcomes and should not be recommended in patients with sICAS. Further research to identify subgroups of patients who could also serve as candidates for future interventional trials along with efforts to reduce procedure-related complications are needed.

Published
2016
Full Text
View/download PDF

34. Mechanical Thrombectomy Global Access For Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study

Author

Asif, Kaiz S., Otite, Fadar O., Desai, Shashvat M., Herial, Nabeel, Inoa, Violiza, Al-Mufti, Fawaz, Jadhav, Ashutosh P., Dmytriw, Adam A., Castonguay, Alicia, Khandelwal, Priyank, Potter-Vig, Jennifer, Szeder, Viktor, Kulman, Tanzila, Urrutia, Victor, Masoud, Hesham, Toth, Gabor, Limaye, Kaustubh, Aroor, Sushanth, Brinjikji, Waleed, Rai, Ansaar, Pandian, Jeyaraj, Gebreyohanns, Mehari, Leung, Thomas, Mansour, Ossama, Demchuk, Andrew M., Huded, Vikram, Martins, Sheila, Zaidat, Osama, Huo, Xiaochuan, Campbell, Bruce, Sylaja, P.N., Miao, Zhongrong, Saver, Jeffrey, Ortega-Gutierrez, Santiago, Yavagal, Dileep R., Cirio, Juan Jose, Lylyk, Pedro, Ferrario, Angel, Plaghos, Luis Lemme, Arroyo, José, Yan, Bernard, Chandra, Ronil, Ibrahim, Wael Hamed, Alnidawi, Firas, Islam, Sirajee Shafiqul, Shahidullah, Mohammad, Saavedra, Víctor Villarroel, Alverne, Francisco Josà Mont’, Magalhaes, Pedro, Silva, Gisele Sampaio, Sirakov, Stanimir, Kalpachki, Rosen, Alioski, Nurfet, lamou, Eric Gueumekane bila, Shankar, Jai, Stotts, Grant, Rowe, Daidre, Gayle, Francene, de Souza, Romnesh, Ramos, Cristina, GarcÃa, Amaury, Ali, Amza, Sandy, Sherry, Lavados, Pablo M., Rivera, Rodrigo, GUZMÁN, TONY FABIÁN ÁLVAREZ, Villarraga, Alejandro, Estrada, Carolina, Pabon, Boris, Krajina, Antonin, Tomek, Aleš, Adebayo, Philip B, ABDO, GERMAN, Maldonado S, Nelson, Hassan, Farouk, Khedr, Eman M, Khinikadze, Mirza, NADAREISHVILI, ZURAB, Tsiskaridze, Alexander, Syrmos, Nikolaos, Mitsias, Panayiotis, Das, Biplab, Roy, Jayanta, Gupta, Vivek, Gupta, Vipul, Khurana, Dheeraj, Karapurkar, Anil, Stivastava, M.V.Padma, Alurkar, Anand, Sharma, Arvind, Lahoti, Satish, Kumar, Rahul, Kuruttukulam, Gigy Varkey, Sani, Achmad Firdaus, Sari, Ita Muharram, Khassaf, Mustafa, Majid Nassir, Temeem, Sakai, Nobuyuki, Yamagami, Hiroshi, Dababneh, Haitham, Aladham, Farid A., Berdikhojayev, Mynzhylky, Medukhanova, Sabina, Kikano, Raghid, Alaraj, Ali, Ahdab, Rechdi, Zaidi, Wan Asyraf Wan, Kadir, Khairul Azmi Abd, Arauz, Antonio, Gongora, Fernando, Jambaldorj, Ariunaa, XXX, Ganbaatar, Shwe, Zarni Myint, Thit, Win Min, Ranta, Anna, Wu, Teddy, RAYO, ERWIN E., Owolabi, Mayowa, Makanjuola, Akintomiwa, Ahmad, Saima, WASAY, MOHAMMAD, Rashid, Umair, Mernes, Ricardo, Paniagua, Osvaldo, GALLO, MARLA, Moquillaza, Manuel, Collantes, Maria Epifania, Mariano, Manuel M., Kobayashi, Adam, Rodriguez-Mercado, Rafael, Guardia, Rodolfo Alcedo, Imam, Yahia, Ahmed, Ayman Zakaria, Alhazzani, Adel, Al-Jehani, Hosam M., Lee, Wickly, ZELEŇÁK, Kamil, Klepanec, Andrej, KRASTEV, GEORGI, Frol, Senta, Brey, Naeem, Rossouw, Anastasia, De Silva, Prasad, Gunasekera, Harsha, Ranawaka, Udaya, Osman, Haytham, El-Sadig, Sarah M, Suwanwela, Nijasri C., Akarathanawat, Wasan, Tantivatana, Jarturon, Hammami, Nadia, Sassi, Samia Ben, Ozdemir, Atilla Ozcan, Giray, Semih, Lebedynets, Dmytro, Konotopchik, Stanislav, John, Seby, Hussain, Syed Irteza, Novakovic-White, Robin, Ozdemir, Atilla Ozcan, Giray, Semih, Gordon Perue, Gillian L., Then, Ryna, Berrutti, Claudio, Crosa, Roberto, Nguyen, Huy Thang, Le, Huynh Vu, and vu, Tran thanh

Published
2023
Full Text
View/download PDF

35. Erratum to: Allergen immunotherapy for insect venom allergy: protocol for a systematic review

Author

Sangeeta Dhami, Ulugbek Nurmatov, Eva-Maria Varga, Gunter Sturm, Antonella Muraro, Cezmi A. Akdis, Darío Antolín-Amérigo, M. Beatrice Bilò, Danijela Bokanovic, Moises A. Calderon, Ewa Cichocka-Jarosz, Joanna N. G. Oude Elberink, Radoslaw Gawlik, Thilo Jakob, Mitja Kosnik, Joanna Lange, Ervin Mingomataj, Dimitris I. Mitsias, Holger Mosbech, Oliver Pfaar, Constantinos Pitsios, Valerio Pravettoni, Graham Roberts, Franziska Ruëff, Betül Ayşe Sin, and Aziz Sheikh

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below: Funding EAACI and the BM4SIT project (Grant Number 601763) in the European Union’s Seventh Framework Programme FP7.

Published
2017
Full Text
View/download PDF

37. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study

Author

Mitsikostas, D.D. Doskas, T. Gkatzonis, S. Fakas, N. Maltezou, M. Papadopoulos, D. Gourgioti, R. Mitsias, P.

Abstract

Introduction: The efficacy of prolonged-release fampridine (PR-FAM) may extend in multiple sclerosis (MS) beyond walking ability. The objective of this study was to evaluate the effect of PR-FAM treatment on cognition, fatigue, depression, and quality of life (QoL) in adult patients with MS in a real-world setting. Methods: FAMILY was a multi-center, prospective, observational, real-world cohort study of MS patients receiving PR-FAM in the outpatient setting. Patients were treated as per PR-FAM’s local prescribing information for 6 months. Standardized protocols and questionnaires were used to evaluate changes in cognition (PASAT; Paced Auditory Serial Addition Test), fatigue (MFIS; Modified Fatigue Impact Scale), depression (BDI-II; Beck Depression Inventory-II) and QoL (MusiQoL; MS International Quality-of-Life questionnaire, MSIS-29; Multiple Sclerosis Impact Scale: PHYS and PSYCH subscales) at 3 and 6 months compared to baseline. Results: In total, 102 eligible patients from 8 sites in Greece were analysed, of whom 92 completed the study and 10 discontinued. At 6 months, PR-FAM treatment resulted in improvements from baseline in PASAT-3′′ (p = 0.044), MFIS (p

Published
2021

38. Acute reperfusion therapies for acute ischemic stroke patients with unknown time of symptom onset or in extended time windows: an individualized approach

Author

Magoufis, G. Safouris, A. Raphaeli, G. Kargiotis, O. Psychogios, K. Krogias, C. Palaiodimou, L. Spiliopoulos, S. Polizogopoulou, E. Mantatzis, M. Finitsis, S. Karapanayiotides, T. Ellul, J. Bakola, E. Brountzos, E. Mitsias, P. Giannopoulos, S. Tsivgoulis, G.

Subjects
cardiovascular diseases
Abstract

Recent randomized controlled clinical trials (RCTs) have revolutionized acute ischemic stroke care by extending the use of intravenous thrombolysis and endovascular reperfusion therapies in time windows that have been originally considered futile or even unsafe. Both systemic and endovascular reperfusion therapies have been shown to improve outcome in patients with wake-up strokes or symptom onset beyond 4.5 h for intravenous thrombolysis and beyond 6 h for endovascular treatment; however, they require advanced neuroimaging to select stroke patients safely. Experts have proposed simpler imaging algorithms but high-quality data on safety and efficacy are currently missing. RCTs used diverse imaging and clinical inclusion criteria for patient selection during the dawn of this novel stroke treatment paradigm. After taking into consideration the dismal prognosis of nonrecanalized ischemic stroke patients and the substantial clinical benefit of reperfusion therapies in selected late presenters, we propose rescue reperfusion therapies for acute ischemic stroke patients not fulfilling all clinical and imaging inclusion criteria as an option in a subgroup of patients with clinical and radiological profiles suggesting low risk for complications, notably hemorrhagic transformation as well as local or remote parenchymal hemorrhage. Incorporating new data to treatment algorithms may seem perplexing to stroke physicians, since treatment and imaging capabilities of each stroke center may dictate diverse treatment pathways. This narrative review will summarize current data that will assist clinicians in the selection of those late presenters that will most likely benefit from acute reperfusion therapies. Different treatment algorithms are provided according to available neuroimaging and endovascular treatment capabilities. © The Author(s), 2021.

Published
2021

40. Predicting final extent of ischemic infarction using artificial neural network analysis of multi-parametric MRI in patients with stroke.

Author

Hassan Bagher-Ebadian, Kourosh Jafari-Khouzani, Panayiotis D Mitsias, Mei Lu, Hamid Soltanian-Zadeh, Michael Chopp, and James R Ewing

Subjects
Medicine, Science
Abstract

In hemispheric ischemic stroke, the final size of the ischemic lesion is the most important correlate of clinical functional outcome. Using a set of acute-phase MR images (Diffusion-weighted--DWI, T(1)-weighted--T1WI, T(2)-weighted--T2WI, and proton density weighted--PDWI) for inputs, and the chronic T2WI at 3 months as an outcome measure, an Artificial Neural Network (ANN) was trained to predict the 3-month outcome in the form of a voxel-by-voxel forecast of the chronic T2WI. The ANN was trained and tested using 12 subjects (with 83 slices and 140218 voxels) using a leave-one-out cross-validation method with calculation of the Area Under the Receiver Operator Characteristic Curve (AUROC) for training, testing and optimization of the ANN. After training and optimization, the ANN produced maps of predicted outcome that were well correlated (r = 0.80, p

Published
2011
Full Text
View/download PDF

42. Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity

Author

Tsivgoulis, G., primary, Goyal, N., additional, Katsanos, A. H., additional, Malhotra, K., additional, Ishfaq, M. F., additional, Pandhi, A., additional, Frohler, M. T., additional, Spiotta, A. M., additional, Anadani, M., additional, Psychogios, M., additional, Maus, V., additional, Siddiqui, A., additional, Waqas, M., additional, Schellinger, P. D., additional, Groen, M., additional, Krogias, C., additional, Richter, D., additional, Saqqur, M., additional, Garcia‐Bermejo, P., additional, Mokin, M., additional, Leker, R., additional, Cohen, J. E., additional, Magoufis, G., additional, Psychogios, K., additional, Lioutas, V. A., additional, Van Nostrand, M., additional, Sharma, V. K., additional, Paciaroni, M., additional, Rentzos, A., additional, Shoirah, H., additional, Mocco, J., additional, Nickele, C., additional, Mitsias, P. D., additional, Inoa, V., additional, Hoit, D., additional, Elijovich, L., additional, Arthur, A. S., additional, and Alexandrov, A. V., additional

Published
2020
Full Text
View/download PDF

44. A Mechanistic and pathophysiological approach for stroke associated with drugs of abuse

Author

Tsatsakis, A. Docea, A.O. Calina, D. Tsarouhas, K. Zamfira, L.-M. Mitrut, R. Sharifi-Rad, J. Kovatsi, L. Siokas, V. Dardiotis, E. Drakoulis, N. Lazopoulos, G. Tsitsimpikou, C. Mitsias, P. Neagu, M.

Subjects
cardiovascular diseases
Abstract

Drugs of abuse are associated with stroke, especially in young individuals. The major classes of drugs linked to stroke are cocaine, amphetamines, heroin, morphine, cannabis, and new synthetic cannabinoids, along with androgenic anabolic steroids (AASs). Both ischemic and hemorrhagic stroke have been reported due to drug abuse. Several common mechanisms have been identified, such as arrhythmias and cardioembolism, hypoxia, vascular toxicity, vascular spasm and effects on the thrombotic mechanism, as causes for ischemic stroke. For hemorrhagic stroke, acute hypertension, aneurysm formation/rupture and angiitis-like changes have been implicated. In AAS abuse, the effect of blood pressure is rather substance specific, whereas increased erythropoiesis usually leads to thromboembolism. Transient vasospasm, caused by synthetic cannabinoids, could lead to ischemic stroke. Opiates often cause infective endocarditis, resulting in ischemic stroke and hypereosinophilia accompanied by pyogenic arthritis, provokinghemorrhagic stroke. Genetic variants are linked to increased risk for stroke in cocaine abuse. The fact that case reports on cannabis-induced stroke usually refer to the young population is very alarming. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Published
2019

49. Unilateral thalamic infarction presenting as vertical gaze palsy: a case report

Author

Mitsias Panayiotis, Sidiropoulos Christos, and Khan Muhib

Subjects
Medicine
Abstract

Abstract Introduction Vertical gaze palsy is a recognized manifestation of midbrain lesions. It rarely is a consequence of unilateral thalamic infarction. Case presentation We report the case of a 48-year-old African-American woman who presented to our facility with vertical gaze palsy and evidence of left medial thalamic infarct on diffusion-weighted imaging without coexisting midbrain ischemia. The etiology of infarct was determined to be small vessel disease after extensive investigation. Conclusions This report suggests a possible role of the thalamus as a vertical gaze control center. Clinicoradiological studies are needed to further define the role of the thalamus in vertical gaze control.

Published
2011
Full Text
View/download PDF

50. Direct oral anticoagulant-vs Vitamin K antagonist-related nontraumatic intracerebral hemorrhage

Author

Tsivgoulis, G. Lioutas, V.-A. Varelas, P. Katsanos, A.H. Goyal, N. Mikulik, R. Barlinn, K. Krogias, C. Sharma, V.K. Vadikolias, K. Dardiotis, E. Karapanayiotides, T. Pappa, A. Zompola, C. Triantafyllou, S. Kargiotis, O. Ioakeimidis, M. Giannopoulos, S. Kerro, A. Tsantes, A. Mehta, C. Jones, M. Schroeder, C. Norton, C. Bonakis, A. Chang, J. Alexandrov, A.W. Mitsias, P. Alexandrov, A.V.

Subjects
cardiovascular diseases, nervous system diseases
Abstract

Objective: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF). Methods: We evaluated consecutive patients with NVAF with nontraumatic, anticoagulantrelated ICH admitted at 13 tertiary stroke care centers over a 12-month period. We also performed a systematic review and meta-analysis of eligible observational studies reporting baseline characteristics and outcomes among patients with VKA-or DOAC-related ICH. Results: We prospectively evaluated 161 patients with anticoagulation-related ICH (mean age 75.66 9.8 years, 57.8% men, median admission NIH Stroke Scale [NIHSSadm] score 13 points, interquartile range 6-21). DOAC-related (n 5 47) and VKA-related (n 5 114) ICH did not differ in demographics, vascular risk factors, HAS-BLED and CHA2DS2-VASc scores, and antiplatelet pretreatment except for a higher prevalence of chronic kidney disease in VKA-related ICH. Patients with DOAC-related ICH had lower median NIHSSadm scores (8 [3-14] vs 15 [7-25] points, p 5 0.003), median baseline hematoma volume (12.8 [4-40] vs 24.3 [11-58.8] cm3, p 5 0.007), and median ICH score (1 [0-2] vs 2 [1-3] points, p5 0.049). Severe ICH (.2 points) was less prevalent in DOAC-related ICH (17.0% vs 36.8%, p 5 0.013). In multivariable analyses, DOAC-related ICH was independently associated with lower baseline hematoma volume (p 5 0.006), lower NIHSSadm scores (p 5 0.022), and lower likelihood of severe ICH (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.13-0.87, p 5 0.025). In meta-analysis of eligible studies, DOAC-related ICH was associated with lower baseline hematoma volumes on admission CT (standardized mean difference 5 20.57, 95% CI 21.02 to 20.12, p 5 0.010) and lower in-hospital mortality rates (OR 5 0.44, 95% CI 0.21-0.91, p 5 0.030). Conclusions: DOAC-related ICH is associatedwith smaller baseline hematoma volume and lesser neurologic deficit at hospital admission compared to VKA-related ICH. © 2017 American Academy of Neurology.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results